Reify Health’s $220 Million Series D Funding Round

Morgan Lewis represented Reify Health in the transaction.

Reify Health, a leading provider of solutions that empower the clinical trial ecosystem, announced a $220 million Series D round co-led by Altimeter Capital and Coatue, joined by Dragoneer Investment Group and existing investors ICONIQ Growth, Adams Street, and Battery Ventures.

This round of funding, which brings the company’s valuation to over $4.8 billion, was secured to accelerate the company’s efforts to improve diversity and representation in clinical trial participation.

Reify Health is paving the way to faster, predictable, and more accessible clinical trials. Through its business entities, StudyTeam and Care Access, the company provides best-in-class trial optimization software and transformative clinical trial infrastructure that delivers research directly to more healthcare providers, communities, and patients wherever they are. 

Morgan Lewis partner Carl Valenstein (Picture), and associates Benjamin Stein and Bryan Judd advised Reify Health.

Involved fees earner: Bryan Judd – Morgan Lewis & Bockius; Benjamin Stein – Morgan Lewis & Bockius; Carl Valenstein – Morgan Lewis & Bockius;

Law Firms: Morgan Lewis & Bockius;

Clients: Reify Health;